Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
iTeos Therapeutics ( (ITOS) ) has provided an update.
iTeos Therapeutics announced plans to present new data from its clinical trials and research pipeline in 2025, focusing on its TIGIT:PD-1 therapies. The company aims to enhance its market opportunities and improve the safety profile of its therapies, with a financial runway secured through 2027. Key data readouts are anticipated from ongoing trials, including GALAXIES Lung-201 and GALAXIES H&N-202, while collaborations with GSK are expected to further bolster iTeos’ position in the immuno-oncology landscape.
More about iTeos Therapeutics
iTeos Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative cancer immunotherapies. The company’s primary products target the TIGIT immune checkpoint, aiming to advance treatments for various cancers, such as lung and head and neck cancer. iTeos is collaborating with GSK to leverage combined expertise and resources in this area.
YTD Price Performance: -1.77%
Average Trading Volume: 555,151
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $283.5M
Find detailed analytics on ITOS stock on TipRanks’ Stock Analysis page.
